Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-dummy, placebo and active-controlled study to assess the safety, tolerability and effect of taspoglutide on glycemic control compared to sitagliptin and placebo in patients with type II diabetes mellitus inadequately controlled with metformin.

Next Previous
Search
Trial Profile

A multicenter, randomized, double-dummy, placebo and active-controlled study to assess the safety, tolerability and effect of taspoglutide on glycemic control compared to sitagliptin and placebo in patients with type II diabetes mellitus inadequately controlled with metformin.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Taspoglutide (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms EMERGE-4; T-EMERGE-4
  • Sponsors Roche

    • Most Recent Events

    • 17 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Sep 2010 Results were repoted at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 25 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top